Essex Bio-Technology Limited
HKSE: 1061.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Hian Leng Ngiam
- Employees
- 1,450
- Headquarters
- Zhuhai, China
- IPO year
- 2001
- Market cap
- HK$1.8B
- Website
- https://www.essexbio.com
Loading 1061…
Loading profile data…Frequently asked questions about 1061
What does Essex Bio-Technology Limited (1061.HK) do?
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the t...
Where does 1061.HK trade?
Essex Bio-Technology Limited (1061.HK) trades on the Hong Kong Stock Exchange.
What sector is 1061.HK in?
Essex Bio-Technology Limited (1061.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Essex Bio-Technology Limited?
Hian Leng Ngiam is the chief executive officer of Essex Bio-Technology Limited (1061.HK).
Where is Essex Bio-Technology Limited headquartered?
Essex Bio-Technology Limited is headquartered in China.
Does 1061.HK pay a dividend?
Yes — Essex Bio-Technology Limited (1061.HK) paid a trailing twelve-month dividend of HKD 0.14 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 1061.HK go public?
Essex Bio-Technology Limited (1061.HK) completed its initial public offering in 2001.